Continuous OCR Monitoring Detects Mitochondrial Cardiotoxicity Before Visible Cell Damage
核心洞察
Continuous oxygen consumption rate monitoring using Resipher technology detected mitochondrial dysfunction in iPSC-derived cardiomyocytes days before any morphological changes appeared.
A single 24-hour exposure to cobalt chloride produced lasting, dose-dependent respiration loss, with OCR falling to 0.63-fold of baseline at 50 µM six days after washout.
Bioenergetic profiling revealed ATP-linked respiration fell disproportionately, with coupling efficiency dropping from 46% to 30%, consistent with Complex IV inhibition.
Drug-induced cardiotoxicity (搜索) remains a leading cause of drug attrition and post-market withdrawal, yet current preclinical cardiac safety guidelines under ICH S7B and E14 focus almost exclusively on ion channel electrophysiology—particularly hERG potassium channel (搜索) inhibition. While these assays are essential, they fail to capture the metabolic dimension of cardiac toxicity, leaving a critical blind spot in safety assessment. New data from a collaboration between Cellomatics Biosciences (搜索) and Lucid Scientific (搜索) demonstrate that continuous oxygen consumption rate (OCR) monitoring can detect mitochondrial cardiotoxicity well before any visible cell damage appears, offering a functional metabolic readout that could transform preclinical cardiac safety evaluation.
The Metabolic Gap in Cardiac Safety Screening
Mitochondrial dysfunction is an established mechanism of drug-induced cardiotoxicity (搜索), especially for kinase inhibitors, anthracyclines, and other oncology agents. When a compound impairs oxidative phosphorylation, ATP production in cardiomyocytes falls, driving contractile dysfunction and cell death without necessarily triggering an ion channel alert. As the researchers note, "a cardiac safety screen built on electrophysiology alone can miss this liability entirely."
The Resipher platform from Lucid Scientific (搜索) addresses this gap by measuring OCR—a direct functional readout of mitochondrial respiration—continuously over days to weeks in standard 96-well plates. High-resolution optical sensors embedded in a sensing lid track live-cell respiration inside the incubator without requiring assay media swaps, fluorescent dyes, or plate transfers. Applied to iPSC-derived cardiomyocytes, the system provides a sensitive window into mitochondrial health across a full compound exposure and recovery period.
Study Design and Key Findings
In the study conducted with Cellomatics Biosciences (搜索) in Nottingham, UK, human iPSC-derived ventricular cardiomyocytes were matured over seven days, then exposed for 24 hours to cobalt chloride (CoCl₂), a model cardiotoxicant and Complex IV inhibitor. The compound was subsequently removed, and OCR was followed for a further six days.
The results revealed a striking subclinical window. A single 24-hour exposure produced lasting, dose-dependent respiration loss. Six days after washout, OCR at 25 µM and 50 µM had fallen to 0.79-fold and 0.63-fold of the pre-treatment baseline, respectively—well below control cells that continued to mature. Critically, the effect was not obvious at any single moment. At 24 hours post-dosing, suppression looked mild and dose-independent. Only by following the cells continuously did the true, dose-ordered effect become clear, as treated wells stopped tracking the maturation-driven rise seen in controls.
Brightfield imaging showed intact, confluent monolayers at every concentration through Day 12. In a standard screen scored on morphology, these doses would have been classified as inactive. Continuous OCR monitoring identified the subclinical metabolic liability—precisely the type most likely to surface as delayed cardiotoxicity in vivo.
From Safety Flag to Mechanism in a Single Experiment
Beyond detection, the platform enabled mechanistic characterization within the same experiment. Bioenergetic profiling using electron transport chain modifiers revealed that ATP-linked respiration fell disproportionately relative to maximal respiration, and coupling efficiency dropped from 46 percent to 30 percent at the highest dose. This pattern is consistent with Complex IV (cytochrome c oxidase) (搜索) inhibition, the primary mechanism of cobalt toxicity, demonstrating that one platform can move from safety flag to mechanism without additional experiments.
The full safety and mechanistic dataset was generated from a single 14-day experiment with no assay media swap or reagent injections. As the authors conclude, Resipher "adds a metabolic safety dimension that electrophysiology-based assays do not provide." Used alongside existing cardiac safety screens, the technology enables earlier, more complete characterization of compound liability, reducing the risk of metabolic cardiotoxicity advancing through late-stage development.